<DOC>
	<DOCNO>NCT00325936</DOCNO>
	<brief_summary>Abnormalities glucose , insulin lipoprotein metabolism common patient hypertension , metabolic abnormality report related insulin resistance . Therefore , whenever treat patient , antihypertensive agent may add effect improve insulin resistance select . CinalongTM ( Cilnidipine ) expect improve metabolic syndrome well insulin resistance dual effect L N-type calcium ( Ca ) channel . In study , researcher investigate effect CinalongTM insulin resistance metabolic related factor .</brief_summary>
	<brief_title>The Effects Cilnidipine Metabolic Syndrome Improvement</brief_title>
	<detailed_description>- Multi-center , randomize , prospective , double blind , active control , parallel study - Superiority study ( Treatment group - Cilnidipine/Control group - Nifedipine ) - Measure effect Cinalong ( TM ) 3 month 12 month-application</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<mesh_term>Cilnidipine</mesh_term>
	<criteria>1 . Men woman , 3065 year age essential hypertension metabolic syndrome 2 . At Screening Visit 1 , blood pressure : sit systolic blood pressure ( SiSBP ) &gt; =140 mmHg sit diastolic blood pressure ( SiDBP ) &gt; = 90 mmHg two follow criterion apply . Abdominal obesity : waist circumference &gt; = 90 cm men &gt; = 80 cm woman Hypertriglyceridemia : . &gt; =150 mg/dl ( 1.695 mmol/l ) Low HDL cholesterol : &lt; 40 mg/dl ( 1.036 mmol/l ) men &lt; 50 mg/dl ( 1.295 mmol/l ) woman High fast glucose : &gt; = 110 mg/dl ( 6.1 mmol/l ) 1 . Secondary hypertension 2 . Malignant hypertension</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>metabolic syndrome</keyword>
	<keyword>Hypertension</keyword>
	<keyword>CCB</keyword>
	<keyword>cilnidipine</keyword>
</DOC>